"Approved Combinations and Novel Agents Expand Therapy Options Across Multiple Myeloma Settings" - Krithika Subramanian
The addition of novel agents and combinations to the treatment of multiple myeloma, along with improvements in personalized therapy based on genetic profiles of individual patients, are propelling care forward with their potential for prolonging survival and deepening responses beyond those from the current standards of care. “STORM Part 2 represents the largest, most heavily pretreated population with MM in a prospective clinical trial to date,” said Ajai Chari, MD, associate professor, hematology and medical oncology, Mount Sinai Hospital. He added, “Patients received a median of seven prior therapies over 6.6 years. These patients have no known available therapies with clinical benefit.”
— Ajai Chari, MD, Director, Clinical Research in the Multiple Myeloma Program, Associate Director, Clinical Research, Mount Sinai Cancer Clinical Trials Office, Associate Professor, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai
Unprecedented Therapy Found Effective for Blood Cancer Patients With No Treatment Options
Aug 22, 2019 View All Press Releases